$2500 | Single User
$5000 | Site License
$7500 | Enterprise License

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016
[Published by Global Data]

Published by Global Data: 30 Aug 2016 | 27418 | In Stock
Related Topics: Clinical Trials , Multiple Myeloma , Myeloma

Introduction

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016" provides an overview of Multiple Myeloma (Kahler Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
for Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016 [Published by Global Data]

  • Table of Contents

    Table of Contents 2

    List of Tables 3

    List of Figures 4

    Report Guidance 5

    Clinical Trials by Region 6

    Clinical Trials and Average Enrollment by Country 7

    Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

    Top Five Countries Contributing to Clinical Trials in Europe 11

    Top Countries Contributing to Clinical Trials in North America 12

    Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13

    Top Five Countries Contributing to Clinical Trials in Central and South America 14

    Clinical Trials by G7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials 15

    Clinical Trials by Phase in G7 Countries 16

    Clinical Trials in G7 Countries by Trial Status 17

    Clinical Trials by E7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials 18

    Clinical Trials by Phase in E7 Countries 19

    Clinical Trials in E7 Countries by Trial Status 20

    Clinical Trials by Phase 21

    In Progress Trials by Phase 22

    Clinical Trials by Trial Status 23

    Clinical Trials by End Point Status 24

    Subjects Recruited Over a Period of Time 25

    Clinical Trials by Sponsor Type 26

    Prominent Sponsors 27

    Top Companies Participating in Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials 28

    Prominent Drugs 30

    Latest Clinical Trials News on Multiple Myeloma (Kahler Disease) 31

    Sep 14, 2016: GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple Myeloma 31

    Sep 09, 2016: Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level 31

    Sep 06, 2016: Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma 31

    Aug 30, 2016: Karyopharm to Host Conference Call with Update on Multiple Myeloma Plans 34

    Aug 25, 2016: Data from Phase III CASTOR Study of Daratumumab Published in The New England Journal of Medicine 34

    Aug 19, 2016: Additional two centers started screening of Multiple Myeloma patients in OV’s APO010 Study 35

    Jul 25, 2016: Daratumumab (DARZALEX) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma 36

    Jul 13, 2016: Immunotherapy benefits relapsed stem cell transplant recipients 37

    Jul 07, 2016: Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 data for DARZALEX (daratumumab) and the Janssen Immuno-oncology Strategy and Portfolio 37

    Clinical Trial Profile Snapshots 38

    Appendix 1662

    Abbreviations 1662

    Definitions 1662

    Research Methodology 1663

    Secondary Research 1663

    About GlobalData 1664

    Contact Us 1664

    Disclaimer 1664

    Source 1665

List Of Tables
in Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016 [Published by Global Data]

List of Tables

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region, 2016* 6

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14

Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase, 2016* 21

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

List Of Figures, Charts and Diagrams
in Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016 [Published by Global Data]

List of Figures

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14

Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

GlobalData Methodology 1663

Additional Details

Publisher

Global Data

Publisher Information

Reference

27418 | GDHC3734CTIDB

Number of Pages

1665

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?
Scope Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis ...
25 Nov 2014 by FirstWord Pharma USD $695 More Info
KOL Insight: Multiple Sclerosis
IntroductionRecent launches of oral therapies have brought clinical advantages and clear patient ben...
06 Oct 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
18 Jun 2014 by FirstWord Pharma USD $695 More Info
Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?
Scope The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in par...
05 May 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Life-cycle management strategies in multiple sclerosis – can new versions of Copaxone, Avonex drive market share retention?
Scope With Copaxone and Avonex generating global sales of .3 billion and billion for Teva and B...
26 Mar 2014 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis: KOL Insight
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
01 Dec 2013 by FirstWord Pharma USD $7,900 More Info
Consensus Outlook: Multiple Sclerosis
IntroductionOver the next five years, the global multiple sclerosis (MS) market is set to grow from ...
01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
Physician Views – Which multiple sclerosis players do the best marketing job? – FirstWord polls neurologists in the US and 5EU
ScopeThe multiple sclerosis market has undergone notable change over the past 2 years, primarily due...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it?
ScopeWith Sanofi securing European approval for its multiple sclerosis therapy Lemtrada last week, n...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
12 Mar 2013 by FirstWord Pharma USD $7,495 More Info

This report is published by Global Data

Download Free Report Summary PDF

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...